465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
HDM1702 Obesity Disorder	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P3	NR ()
huc2-676 Obesity Disorder	Huons Co., Ltd.	P1	NR ()
In-B00009 Obesity Disorder	HK inno.N Corporation	P3	NR ()
ism8969 tablets or Obesity Disorder	InSilico Medicine Hong Kong Limited	P1	NR ()
Kidney Bean Allergenic Extract Obesity Disorder	NovoBliss Research Pvt Ltd	N/A	NR ()
LAE102 Obesity Disorder	Shanghai Zhongshan Hospital	P2	NR ()
Rdx-002 Obesity Disorder	Response Pharmaceuticals	P2	NR ()
s1b-509 high dose Obesity Disorder	S1 Biopharma, Inc.	P2	NR ()
s1b-509 low dose Obesity Disorder	S1 Biopharma, Inc.	P2	NR ()
Sgb-7342 Obesity Disorder	Suzhou Sanegene Bio Inc.	P1	NR ()
Srsd384 Obesity Disorder	Sirius Therapeutics Co., Ltd.	P1/2	NR ()
syh2082 Obesity Disorder	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1	NR ()
Synt101 Obesity Disorder	Syntis Bio	P1	NR ()
Vibegron Obesity Disorder	Wake Forest University Health Sciences	P3	NR ()
xtl6001 Obesity Disorder	Shanghai Xitaili Biomedicine Technology co., Ltd.	P1	NR ()

Showing 451 to 465 of 465 assets

PreviousPage 10 of 10Next